Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Relief therapeutics   /   Relief therapeutics Holding

Aandeel RELIEF THERAPEUTICS N ZSE:RLF.CH, CH1251125998

Laatste koers (chf) Verschil Volume
4,350   +0,320   (+7,94%) Dagrange 3,720 - 4,350 109.960   Gem. (3M) 138,5K

Relief therapeutics Holding

Volgen
9.105 Posts
Pagina: «« 1 ... 406 407 408 409 410 ... 456 »» | Laatste | Omlaag ↓
  1. [verwijderd] 15 juni 2021 17:05
    Het is erg moeilijk de percentages te duiden omdat het EAP programma voor de zwaarste patiënten groep is als andere optie's niet werken en de andere ICU onderzoeken erg verschillende uitkomsten laten zien.

    journals.plos.org/plosone/article?id=...
    "After exclusion of hospitalized patients, the hospital and MV-related mortality rates were 21.6% and 26.5% respectively. "

    "Reports of ICU mortality due to COVID-19 around the world and in the Unites States, in particular, have ranged from 20–62% [7]. In mechanically ventilated patients, mortality has ranged from 50–97%. Observations from Wuhan have shown mortality rates of approximately 52% in COVID-19 patients with ARDS [21]. Cohorts in New York have shown a mortality rate in the mechanically ventilated population as high as 88.1%"

    ". Our lower mortality could be partially explained by our lower average patient age or higher proportion of Non-African Americans as some studies have suggested a higher mortality in the African American population [26]. "

    Het EAP programma bestaat mogelijk uit wat jongere mensen maar die zijn dan wel zeer ernstig ziek. Op gebied van HFNC zijn de resultaten van deze erg zware groep patiënten vergelijkbaar met de totale ICU groep van een goed presterend ziekenhuis. Persoonlijk vind ik de resultaten heel goed maar met het ontbreken van meer details nog steeds geen overweldigend bewijs.
  2. Djazz 15 juni 2021 21:54

    The EAP data are being provided to FDA as "real world data", in support of the findings from the ZYESAMI™ randomized controlled phase 2b/3 clinical trial.

    Expanded Access Protocol

    Aviptadil Treated

    Phase 2b/3 Trial

    Aviptadil Treated

    N=240

    Discharged or Alive at day 28

    (including palliative care)

    (N=240)

    Discharged or Alive at day 28
    (no palliative care)
    (N=196)

    Alive at day 28

    (N=131)

    All Patients Evaluated

    53% (127/240)

    65% (127/196)

    69% (90/131)

    Non-Invasive Ventilation

    69% (73/106)

    76% (73/96)

    79% (60/76)

    Mechanical Ventilation

    40% (54/134)

    54% (54/100)

    55% (30/55)

    About ZYESAMI™/VIP in COVID-19
    Aviptadil is a synthetic form of Vasoactive Intestinal Polypeptide (VIP) first discovered by the late Prof. Sami Said in 1970, and ZYESAMI™ is named in his honor. Although primarily concentrated in the lung, it was first purified from the intestinal tract. VIP binds specifically to the alveolar type II cell (ATII) in the air sac (alveolus) of the lung, where it has been shown have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, VIP stimulates ATII cells to make the surfactant that must coat the lining of the lungs in order for them to exchange oxygen with the blood. Loss of surfactant causes respiratory failure and alveolar collapse, which are hallmarks of COVID-19.

    COVID-19-related respiratory failure is caused by selective infection of the ATII cell by the SARS-CoV-2 virus. The ATII cells are vulnerable because of their (ACE2) surface receptors, which serve as the route of entry for the virus. Coronavirus infection of the ATII cell shuts down surfactant production, triggers the formation of inflammatory cytokines, and causes cell death (cytopathy.) VIP is shown to upregulate surfactant production, block Coronavirus replication in the ATII cell, block cytokine synthesis, and prevent viral-induced cell death (cytopathy). Other than ZYESAMI™, no currently proposed treatments for COVID-19 specifically target this mechanism of action. ZYESAMI™ is not approved by any regulatory authority, including the FDA and European Medicines Agency. Data provided within this press release are not treatment recommendations.

    About NRx Pharmaceuticals
    NRx (www.nrxpharma.com) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients. In addition to its work on Aviptadil, the United States Food and Drug Administration has granted Breakthrough Therapy Designation and a Special Protocol Agreement to NRx to develop NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022. NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA. NRx is publicly traded on the Nasdaq Global Select Exchange under the stock ticker NRXP.

    Cautionary Note Regarding Forward-Looking Statements
    This announcement of NRx, Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the company's management.

    The company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.
  3. Djazz 15 juni 2021 21:54
    NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol

    JUNE 15, 2021 7:33AM EDT

    - Expanded Access Protocol (EAP) Included 240 ICU Patients Suffering Critical COVID-19 with Respiratory Failure who had Exhausted All Approved Therapies
    - Sixty-Five Percent of Patients Receiving ZYESAMI™ (Aviptadil) and Maximal Intensive Care were Alive at 28 Days
    - Survival was Higher in those Treated with High Flow Nasal Cannula than those Treated with Mechanical Ventilation (76% vs. 54%)
    - Results from EAP are Congruent with the Randomized Control Phase 2b/3 ZYESAMI™ (Aviptadil) Trial Data Submitted to US Food and Drug Administration (FDA) in Support of Emergency Use Authorization (EUA)
    - EAP Data to be Submitted to US FDA in Support of EUA Filing
    RADNOR, Pa., June 15, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage pharmaceutical company, today announced positive data from its ZYESAMI™ (Aviptadil) Expanded Access Protocol (EAP). Overall, patients receiving at least one dose of ZYESAMI™ in addition to intensive care were alive at 28 days. This EAP (https://clinicaltrials.gov/ct2/show/NCT04453839) provided an opportunity for many regional hospitals to offer ZYESAMI™ to its sickest patients, for whom no other options were available, and who could not enroll in a study due to additional risk factors. Fifty-six percent of patients enrolled were already receiving mechanical ventilation, and 44% were receiving non-invasive forms of ventilation, mostly high nasal flow cannula. (HFNC).

    NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Program
    "We initiated the ZYESAMI™ EAP at FDA's request, to gain real-world evidence from patient outcomes outside of the clinical trial environment. Working with 42 U.S. medical centers and hospitals, we were able to see the outcomes ZYESAMI™ provided to some of sickest of COVID-19 patients," said Jonathan Javitt, MD, MPH, CEO and Chairman of the Board, of NRx. "While vaccinations have markedly reduced the incidence of COVID-19 in some countries, effective medicines remain critical for the tens of thousands who continue contracting COVID-19 and the expanding numbers of variants associated with this virus."

    Enrollment in the EAP was offered to patients who were ineligible for the ZYESAMI™ phase 2b/3 clinical trial, and who had exhausted all approved therapies for COVID-19. The enrollment included 240 patients dosed by March 19, 2021, of whom 196 received maximal intensive care. Fifty-six patients received palliative care (withdrawal of life support) as determined by their families and treating physicians. Among patients receiving maximal intensive (i.e. non-palliative) care, 76% of those treated with HFNC were discharged from the hospital or were alive and in the hospital at day 28, compared to 54% of those treated with mechanical ventilation. These numbers are congruent with the previously reported, topline, randomized, clinical data of ZYESAMI™ in Critical COVID-19 patients with respiratory failure. Many of the patients involved in this EAP had prolonged illness or had exclusion factors limiting their access to the randomized clinical trial, and were enrolled as a last resort in this EAP.

    Treatment related adverse events from this EAP are congruent with those seen in the randomized controlled phase 2b/3 clinical trial of ZYESMI™. Treatment related adverse events included diarrhea (5%) and hypotension (5%). Other adverse events included tachycardia and flushing.

    "So many of us have lived the past 16 months in the ICU of our hospitals taking care of desperately-ill patients suffering from the most severe symptoms of COVID-19," said Dr. Eduardo Freitas, Head of Infectious Diseases at Great Plains Health Hospital in North Platte, Nebraska, one of the participating investigators in the EAP. "A regional hospital like ours is not typically involved in clinical studies, and we greatly appreciate the opportunity to participate in the Aviptadil EAP. Every doctor caring for COVID-19 patients needs new medicines to help those critically ill with this virus recover and get back to their homes and families."
  11. Beso 17 juni 2021 10:46
    opnieuw interessante quote van Bert-Jan op Yahoo forum :

    COVID-19 case numbers continue to decline but no end to the pandemic is in sight. Several clinicians in Europe have expressed the wish to participate in the COVID-19 study with inhaled aviptadil under the leadership of Prof. Leuppi. We were informed yesterday of the EudraCT number required for this. This will allow any hospital within the EU to participate.

    www.linkedin.com/posts/advita-lifesci...
  13. Beso 23 juni 2021 15:00
    @Reader : zou het helpen om dat dak van jou er hier af te doen gaan door de plaat op te zetten "kom van dat dak af"?
    Hopelijk is het de stilte voor de mooie storm want in 2 dagen geen enkele post op dit forum en koersvolume ook heel laag.
    Iedereen zit denk ik op zijn positie en is aan het wachten op goed nieuws.
  18. Beso 23 juni 2021 17:26
    Ligt de Delta variant aan de basis van 12 doden ondanks 2x met Pfizer gevaccineerd?
    Indien ja, dan is het des te belangrijker om Aviptadil te hebben en is het voor RLF verre van te laat.
    Stelt zich ook de vraag hoe lang het nog gaat duren vooraleer de volgende variant opduikt waartegen de vaccins niet opgewassen zijn?

    Recent artikel uit de krant Nieuwsblad :
    MONSTREUX / NIVELLES / BAULERS / THINES / BORNIVAL - Bij een corona-uitbraak in een woonzorgcentrum in Nijvel zijn twaalf mensen overleden. Opvallend, want zij waren voor de uitbraak wel degelijk gevaccineerd. Hoe het virus is binnengeraakt en hoe het komt dat er nog zoveel overlijdens te betreuren zijn, wordt verder onderzocht.
    De uitbraak in het rusthuis Nos Tayons dateert van vorige maand, maar nu wordt stilaan duidelijk hoe erg ze was. 59 van de 119 bewoners raakten besmet, 12 bewoners overleden aan het coronavirus en enkelen liggen nog steeds in het ziekenhuis.

    Nochtans was meer dan 95 procent van de bewoners volledig gevaccineerd met het Pfizer-vaccin. Bij het personeel lag de vaccinatiegraad iets lager, daar was 75 procent gevaccineerd.

    Onderzoek

    De Waalse tegenhanger van Sciensano, Aviq, is intussen met een uitgebreid onderzoek gestart. Onder andere de bewaring, maar ook de toediening van de vaccins wordt onder de loep genomen. In het woonzorgcentrum werd deze week een luchtfilter geplaatst die een continue analyse van de lucht zal maken. Bezoekers zijn voorlopig niet toegelaten bij de bewoners.

    Wat wel al duidelijk is, is dat de bewoners besmet raakten met de deltavariant (vroeger Indiase, nvdr.). Die is nog besmettelijker dan de Britse variant en leidt ook vaker tot een ziekenhuisopname. En de variant wint aan kracht. Naar schatting zal de deltavariant midden juli de dominante variant zijn in ons land.

    Is het door die variant dat er mensen overleden zijn ondanks vaccinatie? “Moeilijk om daar nu al de vinger op te leggen”, zegt vaccinoloog Pierre Van Damme (UAntwerpen). “Het gaat hier wel om de meest kwetsbare groep van de bevolking. De vraag is dus ook of ze effectief allemaal aan het coronavirus gestorven zijn? Welke andere factoren hebben meegespeeld? Dat wordt nu onderzocht.”
9.105 Posts
Pagina: «« 1 ... 406 407 408 409 410 ... 456 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee